Highlights Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 02:29:40 08/07/2025 pm IST			5-day change	1st Jan Change
82.12 ^EUR	-0.39%		-1.14%	-12.40%

11:01am	SANOFI : UBS maintains a Buy rating	ZD
03/07	SANOFI : Goldman Sachs reiterates its Neutral rating	ZD

Highlights

Berenberg Keeps Sanofi at Buy on Expanding Pipeline Optionality	03/07	MT
Adagene ADRs Rise Following Sanofi Investment	01/07	DJ
Adagene to Receive up to $25 Million Investment From Sanofi; Shares up Pre-Bell	01/07	MT
Euroapi: sells Haverhill site in UK	01/07	CF
Esteve Pharmaceuticals, S.A. agreed to acquire Caprelsa® rights in more than 50 countries from Sanofi.	01/07	CI
Sanofi Advances Rare Neurological Disorder Treatment with Orphan Drug Status in Japan	30/06	MT
Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy	30/06	CI
Sanofi's Riliprubart Secures Orphan Drug Designation in Japan	30/06	MT
Kennedy's US vaccine panel backs preservative-free shot despite safety evidence	27/06	RE
Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies	26/06	RE
Kymera Therapeutics, Inc. Provides Update on Collaboration with Sanofi for Drug Candidate KT-485	25/06	CI
Kymera Announces Sanofi to Advance KT-485 Into Clinical Testing	25/06	MT
Sanofi's Riliprubart Receives Orphan Drug Designation from US FDA	25/06	MT
US CDC vaccine presentation cites study that does not exist, author says	25/06	RE
US CDC vaccine presentation cites study that does not exist, author says	25/06	RE
Sanofi's Multiple Myeloma Treatment Recommended for Approval in EU	23/06	MT
Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent for the Treatment of Adult Patients with Bullous Pemphigoid	20/06	CI
Sanofi and Regeneron's Dupixent Approves in the US as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid	20/06	CI
Sanofi Says FDA Approved Dupixent In The US For Treatment Of Adult Patients With Bullous Pemphigoid	20/06	RE
Sanofi Obtains US FDA Approval for Dupixent as Treatment for Bullous Pemphigoid	20/06	MT
Sanofi Signs Vaccine Development MOU With Abu Dhabi	19/06	MT
The Department of Health - Abu Dhabi and Sanofi Forge Strategic Alliance to Accelerate the Development of New Global Vaccines in Abu Dhabi	19/06	CI
BofA Keeps Sanofi at Buy, Says Positive Amlitelimab Data a 'Must Have' for R&D Rebound	18/06	MT
Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May	17/06	MT
Trump Administration to Consider Pharma Advertising Crackdown	17/06	MT